Pharmacovigilance – News and Features

Identifying a key protein’s role in benzodiazepine-related side effects could improve the common mental health medications and point to new treatments for inflammation-related diseases.

UC Davis researchers developed JRT, a modified version of LSD that promotes neuroplasticity without hallucinogenic effects. Tested in mice, JRT enhanced brain connectivity, showed antidepressant effects and improved cognition.

Research from the Keck School of Medicine has found that COVID-19 therapies cause few serious side effects, based on an evaluation of the full spectrum of evidence available from U.S. biomedical science.

A clinical study has found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to their liver.

A study identifies a brain pathway linking inflammation to dopamine loss and apathy in cancer. Researchers found that IL-6 activates brainstem neurons that suppress motivation. Blocking this circuit restored motivation in mice.

The FDA has announced plans to replace animal testing for many drugs in favor of AI and human-based lab models. The new approach is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation.

Researchers have developed the first wearable device for measuring gases emitted from and absorbed by the skin, allowing for a new way to measure skin health, wound healing, hydration levels and more.

Researchers have developed a new nanoparticle therapy that tackles obesity through two complementary mechanisms: converting energy-storing white fat into calorie-burning beige fat while simultaneously reducing obesity-related inflammation.

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are associated with a decrease in the consumption of processed foods, sugary drinks and red meat.

A clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, demonstrated a 31% delay in the onset of six-month confirmed disability progression in patients with non-relapsing secondary progressive multiple sclerosis.